Neogenomics (NEO) Cash & Current Investments (2010 - 2026)

Neogenomics has reported Cash & Current Investments for 17 years, with the latest figure at $146.1 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Current Investments fell 59.19% year-over-year to $146.1 million; the trailing twelve-month figure through Mar 2026 stood at $146.1 million (down 59.19% YoY), and the FY2025 full-year result was $159.6 million, down 58.74% from the prior year.
• Cash & Current Investments for Q1 2026 stood at $146.1 million, down from $159.6 million in the prior quarter.
• The five-year high for Cash & Current Investments was $481.4 million in Q1 2022, with the low at $146.1 million in Q1 2026.
• Historically, Cash & Current Investments has averaged $353.7 million across 5 years, with a median of $387.9 million in 2024.
• Annual changes were most pronounced in 2024 — Cash & Current Investments declined 3.59% — and 2026, when it plunged 59.19%.
• Neogenomics' Cash & Current Investments stood at $438.0 million in 2022, then declined by 5.2% to $415.2 million in 2023, then dropped by 6.83% to $386.8 million in 2024, then slumped by 58.74% to $159.6 million in 2025, then decreased by 8.44% to $146.1 million in 2026.
• The last three Cash & Current Investments figures came in at $146.1 million (Q1 2026), $159.6 million (Q4 2025), and $164.1 million (Q3 2025), per Business Quant data.